A Phase 1 randomised, double-blind, placebo-controlled study to assess the safety and tolerability of Bacteroides thetaiotaomicron in young people aged 16 to 18 years with stable Crohn's disease.

Trial Profile

A Phase 1 randomised, double-blind, placebo-controlled study to assess the safety and tolerability of Bacteroides thetaiotaomicron in young people aged 16 to 18 years with stable Crohn's disease.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Bacteroides thetaiotaomicron (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; First in man
  • Sponsors 4D Pharma PLC
  • Most Recent Events

    • 26 Jun 2017 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
    • 26 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top